脑转移瘤放疗后初发及复发放射性对比增强的管理:贝伐珠单抗与皮质类固醇的临床和影像学影响
该回顾性分析纳入95例脑转移瘤放疗后出现放射性对比增强(RICE)的患者,中位随访28.8个月。贝伐珠单抗联合皮质类固醇在改善临床症状和影像学特征方面分别达65.9%和75.6%,均显著优于单用皮质类固醇,并将RICE无进展生存期延长至中位5.6个月。RICE复发率为63.1%,再照射后更常见,复发后死亡率36.6%,多次贝伐珠单抗治疗可获得良好应答。
要点
- 贝伐珠单抗联合皮质类固醇改善RICE症状和影像学分别达65.9%和75.6%,优于单用皮质类固醇。
- 联合治疗将RICE无进展生存期延长至中位5.6个月。
- RICE复发率63.1%,再照射后更常见,复发后死亡率36.6%,多次贝伐珠单抗治疗应答良好。
核心结论
- 贝伐珠单抗联合皮质类固醇在实现RICE短期影像学和症状改善方面优于单用皮质类固醇,并延长无进展时间。
- 停用贝伐珠单抗后长期RICE flare-up( flare-up)发生率 high,但重复治疗可实现有效的症状控制。
研究设计与样本
- 回顾性识别脑转移瘤接受放疗后发生RICE的患者,共95例,中位随访28.8个月。
- 回顾患者人口学和临床数据、放疗、癌症及RICE治疗、影像学结果和肿瘤学结局。
主要发现
- RICE在首次放疗后中位8.0个月、再照射后中位6.4个月出现。
- 贝伐珠单抗联合皮质类固醇在65.9%的病例中改善临床症状、在75.6%的病例中改善影像学特征,均显著优于单用皮质类固醇。
- 联合治疗将RICE无进展生存期显著延长至中位5.6个月。
- 初始影像学改善或稳定后RICE复发率为63.1%,再照射后患者显著更常见,复发诊断后死亡率为36.6%。
- 复发应答显著取决于所采用的治疗,多疗程贝伐珠单抗获得良好应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The appearance of radiation-induced contrast enhancements (RICE) after radiotherapy for brain metastases can go along with severe neurological impairments. The aim of our analysis was to evaluate radiological changes, the course and recurrence of RICE and identify associated prognostic factors. METHODS: We retrospectively identified patients diagnosed with brain metastases, who were treated with radiotherapy and subsequently developed RICE. Patient demographic and clinical data, radiation-, cancer-, and RICE-treatment, radiological results, and oncological outcomes were reviewed in detail. RESULTS: A total of 95 patients with a median follow-up of 28.8 months were identified. RICE appeared after a median time of 8.0 months after first radiotherapy and 6.4 months after re-irradiation. Bevacizumab in combination with corticosteroids achieved an improvement of clinical symptoms and imaging features in 65.9% and 75.6% of cases, respectively, both significantly superior compared to treatment with corticosteroids only, and further significantly prolonged RICE-progression-free survival to a median of 5.6 months. Recurrence of RICE after initially improved or stable imaging occurred in 63.1% of cases, significantly more often in patients after re-irradiation and was associated with high mortality of 36.6% after the diagnosis of flare-up. Response of recurrence significantly depended on the applied treatment and multiple courses of bevacizumab achieved good response. CONCLUSION: Our results suggest that bevacizumab in combination with corticosteroids is superior in achieving short-term imaging and symptom improvement of RICE and prolongs the progression-free time compared to corticosteroids alone. Long-term RICE flare-up rates after bevacizumab discontinuation are high, but repeated treatments achieved effective symptomatic control.
引用
- Meixner E, Hörner-Rieber J, Lischalk JW, et al. Management of initial and recurrent radiation-induced contrast enhancements following radiotherapy for brain metastases: Clinical and radiological impact of bevacizumab and corticosteroids. Clin Transl Radiat Oncol. 2023. PMID: 36873269. doi:10.1016/j.ctro.2023.100600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。